Slide 1: ARV-766: Phase 1 and interim Phase 2 data
1 June 8, 2023 ARV-766: Phase 1 and interim Phase 2 data
Slide 2: Safe harbor and forward-looking statements
Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential advantages and therapeutic bene
Slide 3: ARV-766 is showing promising efficacy signals in late-line mCRPC and is well-tolerated
ARV-766 is showing promising efficacy signals in late-line mCRPC and is well- tolerated, supporting its potential as an earlier-line treatment 3 ARV-766 is showing promising efficacy signals in a heavily pretreated patients, including in patients with androgen receptor (AR) L702H mutations • 42% of
Slide 4: ARV-766: A novel AR degrader designed to address multiple resistance mechanisms, including AR L702H
ARV-766: A novel AR degrader designed to address multiple resistance mechanisms, including AR L702H point mutations 4 *878X = T878A or T878S; mCRPC, metastatic castrate-resistant prostate cancer; LBD, ligand binding domain 1 Coutinho et al 2016 DOI: 10.1530/ERC-16-0422. 2 Ledet et al 2020 DOI: 10.16
Slide 5: Phase 1/2 trial of ARV-766 is enrolling a post-NHA, heavily pretreated population
The Phase 1/2 trial of ARV-766 is enrolling a post-NHA, all-comers, heavily pretreated patient population 5 Parameters Phase 1 (n=34) Phase 2 (interim data)* (n=13) Median age (range), years 70 (59–86) 67 (60–76) ECOG performance status, n (%) 0 20 (59) 9 (69) 1 14 (41) 4 (31) Visceral disease†, n (
Slide 6: AR LBD Mutations Were Present in 28% of Patients' Tumors in the Phase 1/2 Trial
AR LBD Mutations Were Present in 28% (13 of 47) of Patients’ Tumors in the Phase 1/2 Trial 6 Parameters Phase 1 (n=34) Phase 2 (interim data)† (n=13) AR LBD Mutation Status, n (%) LBD Mutant 10 (29) 3 (23) H875Y/T878X†† without L702H 4 (12) 3 (23) H875Y/T878X†† with L702H 3 (9) 0 (0) L702H alone 2 (
Slide 7: ARV-766 has been well tolerated, with no grade >4 TRAEs and low rates of dose reduction and discontinuation
ARV-766 has been well tolerated, with no grade >4 TRAEs and low rates of dose reduction and discontinuation 7 TRAE >5%, n (%) Total (n=34) Gr 1 Gr 2 Gr 3 Total Any TRAE 9 (27) 7 (21) 2 (6) 18 (53) Fatigue 3 (9) 3 (9) 1 (3) 7 (21) Nausea 2 (6) 2 (6) 0 (0) 4 (12) Diarrhea 3 (9) 1 (3) 0 (0) 4 (12) Vomi
Slide 8: Patients with co-occurring AR H875/T878/L702H mutations achieved best PSA reductions >50%
3 of 3 patients with co-occurring AR H875/T878/L702H mutations achieved best PSA reductions >50%1 8 1 Analysis includes biomarker-evaluable, AR LBD-positive patients with ≥4 weeks of PSA follow-up. LBD, ligand-binding domain; PSA, prostate-specific antigen; PSA30, best PSA declines ≥30%; PSA50, best
Slide 9: Arvinas' AR franchise is on track for development across the treatment landscape in mCRPC and CSPC
Arvinas’ AR franchise is on track for development across the treatment landscape in mCRPC and CSPC 9 Bavdegalutamide: Phase 3 trial in mCRPC to initiate in 2H23 • Precision medicine opportunity in a growing population with few treatment options ⎻ In the U.S. alone: Addressable population of 8,000-11